

CITATION REPORT

List of articles citing

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

DOI: 10.1182/blood-2015-03-633537
Blood, 2015, 126, 233-41.

Source: <https://exaly.com/paper-pdf/62260280/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
327	Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. 2015 , 2015, 19-25		23
326	Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. 2015 , 3, 952-4		4
325	Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. <i>British Journal of Haematology</i> , 2015 , 171, 478-90	4.5	23
324	Splicing up the classification of myelodysplasia. <i>Blood</i> , 2015 , 126, 128-9	2.2	1
323	Cytopenias + mutations - dysplasia = what?. <i>Blood</i> , 2015 , 126, 2349-51	2.2	12
322	The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications. 2015 , 27, 551-9		5
321	Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3Nsplice Site Selection through Use of a Different Branch Point. 2015 , 13, 1033-45		260
320	Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?. 2015 , 10, 282-91		30
319	. 2016 ,		2
318	Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. <i>British Journal of Haematology</i> , 2016 , 173, 49-58	4.5	23
317	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. 2016 , 146, 86-94		14
316	Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. <i>British Journal of Haematology</i> , 2016 , 172, 512-23	4.5	89
315	New challenges in evaluating anemia in older persons in the era of molecular testing. 2016 , 2016, 67-73		12
314	When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. <i>Blood</i> , 2016 , 128, 2381-2387	2.2	40
313	Treatment of low-risk myelodysplastic syndromes. 2016 , 2016, 462-469		35
312	H2AX deficiency is associated with erythroid dysplasia and compromised haematopoietic stem cell function. 2016 , 6, 19589		4
311	Síndromes mielodisplásicos. 2016 , 12, 1224-1234		

310	Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. 2016 , 30, 2322-2331		70
309	Roles of Fe-S proteins: from cofactor synthesis to iron homeostasis to protein synthesis. 2016 , 38, 45-51		36
308	Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. 2016 , 30, 989-1001		73
307	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016 , 128, 902-10	2.2	93
306	Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. <i>Blood</i> , 2016 , 127, 2361-4	2.2	65
305	The myelodysplastic syndromes. 2016 , 1-79		1
304	Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts. 2016 , 11, 416-424		17
303	Jumping translocations in myelodysplastic syndromes. 2016 , 209, 395-402		7
302	Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells. 2016 , 44, 1188-1196.e6		11
301	Myeloproliferative neoplasms: Morphology and clinical practice. 2016 , 91, 430-3		36
300	Splicing-factor alterations in cancers. 2016 , 22, 1285-301		131
299	How I treat essential thrombocythemia. <i>Blood</i> , 2016 , 128, 2403-2414	2.2	46
298	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood</i> , 2016 , 127, 2391-405	2.2	4986
297	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. <i>Blood</i> , 2016 , 127, 749-60	2.2	34
296	Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. <i>British Journal of Haematology</i> , 2016 , 174, 847-58	4.5	20
295	Autoimmunity and Inflammation in Myelodysplastic Syndromes. 2016 , 136, 108-17		32
294	Spliceosomal component Sf3b1 is essential for hematopoietic differentiation in zebrafish. 2016 , 44, 826-837.e45		45
293	Mitochondrial iron overload: causes and consequences. 2016 , 38, 31-37		40

292	RNA mis-splicing in disease. 2016 , 17, 19-32		563
291	Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. 2016 , 37, 4633-40		32
290	A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. 2017 , 56, 82-87		4
289	Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data. 2017 , 7, 43169		118
288	Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. <i>Blood</i> , 2017 , 129, 1685-1690	2.2	42
287	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 1753-1762	2.2	189
286	The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. 2017 , 15, 131-135		4
285	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017 , 129, 3371-3378	2.2	229
284	The role of RNA alternative splicing in regulating cancer metabolism. 2017 , 136, 1113-1127		55
283	Implications of molecular genetic diversity in myelodysplastic syndromes. 2017 , 24, 73-78		35
282	Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. 2017 , 105, 720-731		13
281	-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. <i>Blood</i> , 2017 , 130, 881-890		38
280	Turning the tide in myelodysplastic/myeloproliferative neoplasms. 2017 , 17, 425-440		91
279	Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures. 2017 , 33, 336-348		43
278	The Myelodysplastic Syndromes and the Myelodysplastic/Myeloproliferative Neoplasms. 2017 , 295-370		
277	How do messenger RNA splicing alterations drive myelodysplasia?. <i>Blood</i> , 2017 , 129, 2465-2470	2.2	20
276	Iron chelation therapy in low risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2017 , 177, 375-387	4.5	8
275	The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. 2017 , 57, 102-103		

274	Dynamics of clonal evolution in myelodysplastic syndromes. 2017 , 49, 204-212	228
273	Splicing factor gene mutations in hematologic malignancies. <i>Blood</i> , 2017 , 129, 1260-1269	2.2 67
272	Individual risk assessment in MDS in the era of genomic medicine. 2017 , 54, 133-140	2
271	Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies. 2017 , 216-217, 128-141	10
270	The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes. 2017 , 5, 139-143	28
269	The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes. 2017 , 30, 295-300	6
268	SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. 2017 , 17, 613-620	3
267	Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics. 2017 , 12, 448-454	3
266	Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. 2017 , 18, 1338-1347	176
265	Mutations of RNA splicing factors in hematological malignancies. 2017 , 409, 1-8	9
264	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints. 2017 , 17S, S16-S25	5
263	Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. 2017 , 17S, S62-S74	14
262	Introduction. 2017 , 54, 129-132	
261	Dyserythropoiesis of myelodysplastic syndromes. 2017 , 24, 191-197	16
260	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. 2017 , 17, 5-19	350
259	Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects. 2017 , 98, 302-310	2
258	Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). 2017 , 58, 1686-1693	12
257	Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts. <i>British Journal of Haematology</i> , 2017 , 178, 813-816	4.5 1

256	Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. 2017 , 23, 3428-3441	59
255	Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. 2017 , 63, 59-70	25
254	Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. 2017 , 7, 630	9
253	Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. 2017 , 7, 663	26
252	Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. 2017 , 12, 461-467	21
251	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. 2017 , 37, 480-494	2
250	Diagnostics and Prognostication of Myelodysplastic Syndromes. 2017 , 37, 465-474	13
249	Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. 2017 , 2017, 3625946	4
248	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. 2017 , 1, 2032-2040	37
247	Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. 2017 , 35, 968-974	72
246	Clonal shifts in MDS - from SF3B1 to EZH2. 2018 , 59, 2994-2997	
245	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. 2018 , 126, 64-79	6
244	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. 2018 , 24, 1834-1844	88
243	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. 2018 , 8, 18	13
242	Myelodysplastic Syndrome. 2018 , 159-171	
241	Dynamics of mutation and prognostic relevance in patients with primary myelodysplastic syndrome. 2018 , 10, 42	22
240	Current status and trends in the diagnostics of AML and MDS. 2018 , 32, 508-519	23
239	Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. 2018 , 69, 90-100	16

238	Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. 2018 , 57, 80-88	21
237	Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches. 2018 , 67, 13-29	17
236	Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. 2018 , 32, 788-800	50
235	The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. 2018 , 97, 247-254	6
234	Mechanisms underlying the heterogeneity of myelodysplastic syndromes. 2018 , 58, 17-26	10
233	Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. 2018 , 93, 129-147	108
232	Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?. 2018 , 64, 24-29	8
231	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. 2018 , 103, 69-79	21
230	Insights from structures of cancer-relevant pre-mRNA splicing factors. 2018 , 48, 57-66	9
229	Treatments targeting MDS genetics: a fool's errand?. 2018 , 2018, 277-285	5
228	The Clinical and Laboratory Features of Clonal Hematopoiesis of Indeterminate Potential. 2018 , 1, 37-42	1
227	Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. 2018 , 19,	18
226	Sideroblastic anemia with myopathy secondary to novel, pathogenic missense variants in the gene. 2018 , 103, e564-e566	4
225	Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes. 2018 , 108, 598-606	7
224	Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes. 2018 , 2018, 6328051	12
223	[WHO classification of myeloid neoplasms]. 2018 , 39, 315-318	
222	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. 2018 , 13, 467-476	4
221	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. 2018 , 9, 3649	76

220	Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. 2018 , 2, 1393-1402		12
219	Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. 2018 , 18, 495-500		1
218	Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. 2018 , 18, 528-532		9
217	Diagnostic algorithm for lower-risk myelodysplastic syndromes. 2018 , 32, 1679-1696		3
216	Myelodysplastic Syndromes. 2018 , 944-969.e13		0
215	SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS. 2018 , 11, 19		19
214	The genetic and molecular pathogenesis of myelodysplastic syndromes. 2018 , 101, 260-271		35
213	Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 717-737	5.1	28
212	Cytopenias: Reactive and Neoplastic. 2018 , 17-79		1
211	Myelodysplastic Syndrome Updated. 2019 , 86, 7-13		20
210	The current approach to the diagnosis of myelodysplastic syndromes. 2019 , 56, 15-21		9
209	A variant erythroferrone disrupts iron homeostasis in -mutated myelodysplastic syndrome. 2019 , 11,		27
208	Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. 2019 , 39, 509-514		5
207	Effect of L-Leucine Therapy on Hematopoietic Function in Elderly Myelodysplastic Syndrome Patients. 2019 , 42, 1651-1657		2
206	Altered RNA Processing in Cancer Pathogenesis and Therapy. 2019 , 9, 1493-1510		52
205	Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. 2019 , 37, 628-633		2
204	CRISPR editing of sftb-1/SF3B1 in <i>Caenorhabditis elegans</i> allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing. 2019 , 15, e1008464		8
203	Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms. 2019 , 12, 651-669		1

202	Somatic mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia. 2019 , 72, 778-782		5
201	Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. 2019 , 86, 106227		1
200	Genetics of MDS. <i>Blood</i> , 2019 , 133, 1049-1059	2.2	118
199	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. 2019 , 33, 2842-2853		19
198	CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. 2019 , 39, 400-410		23
197	Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged \geq 60 years and has lower toxicities: Comparison with low-dose chemotherapy. 2019 , 77, 88-94		1
196	Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. <i>Blood</i> , 2019 , 134, 186-198	2.2	27
195	Diagnosis and Classification of Myelodysplastic Syndrome. 2019 ,		
194	Transforming growth factor (TGF)- β pathway as a therapeutic target in lower risk myelodysplastic syndromes. 2019 , 33, 1303-1312		26
193	Getting personal with myelodysplastic syndromes: is now the right time?. 2019 , 12, 215-224		7
192	Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study. 2019 , 41, 380-386		2
191	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. <i>Blood</i> , 2019 , 134, 2107-2111	2.2	9
190	The splicing factor Sf3b1 regulates erythroid maturation and proliferation via TGF β signaling in zebrafish. 2019 , 3, 2093-2104		7
189	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. 2019 , 3, 3454-3460	2	
188	Molecular Genetics in Myelodysplasia Outcomes Prognostication. 2019 , 2, 35-43		
187	Mutation-Driven Therapy in MDS. 2019 , 14, 550-560		4
186	Application of Genomics to Clinical Practice in Haematological Malignancy. 2019 , 7, 236-252		
185	Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis. 2019 , 98, e15743		5

184	Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. 2019 , 33, 415-425	39
183	Evaluation of SF3B1 Mutation Screening by High-Resolution Melting Analysis and its Clinical Utility for Myelodysplastic Syndrome with Ring Sideroblasts at the Point of Diagnosis. 2019 , 50, 254-262	2
182	Heterogeneity in myeloproliferative neoplasms: Causes and consequences. 2019 , 71, 55-68	23
181	Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS). <i>British Journal of Haematology</i> , 2019 , 185, 954-957	4-5 3
180	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. 2019 , 33, 1747-1758	88
179	Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology. 2019 , 41, 109-117	1
178	Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. 2019 , 133, 74-83	8
177	Splicing factor mutant myelodysplastic syndromes: Recent advances. 2020 , 75, 100655	10
176	A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes. 2020 , 34, 271-282	6
175	Myelodysplastic syndromes. 2020 , 589-602	
174	Novel DDX41 variants in Thai patients with myeloid neoplasms. 2020 , 111, 241-246	9
173	RNA Regulators in Leukemia and Lymphoma. 2020 , 10,	5
172	How we manage adults with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2020 , 189, 1016-1027	28
171	The evolving role of next generation sequencing in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020 , 188, 224-239	4-5 7
170	Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?. 2020 , 33, 101139	1
169	Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity. 2020 , 34, 379-391	0
168	Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options. 2020 , 11, 305-318	8
167	Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. 2020 , 25, 283-285	0

166	The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. 2020 , 9,		5
165	Therapy for lower-risk MDS. 2020 , 2020, 426-433		13
164	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. 2020 , 95, 1399-1420		32
163	Diagnosis and Management of Myelodysplastic Syndromes. 2020 ,		
162	Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 579221	5:3	3
161	Spliceosome Mutations in Uveal Melanoma. 2020 , 21,		4
160	U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing. 2020 , 9,		2
159	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. 2020 , 99, 106472		2
158	Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly. 2020 , 11, 5621		8
157	Toward classifying the unclassifiable. <i>Blood</i> , 2020 , 136, 1800-1801	2.2	1
156	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020 , 136, 157-170	2.2	72
155	How I Diagnose Low-Grade Myelodysplastic Syndromes. 2020 , 154, 5-14		3
154	A 19-year-old patient with atypical chronic myeloid leukemia. 2020 , 99, 1145-1148		
153	Genetic basis of myelodysplastic syndromes. 2020 , 96, 107-121		5
152	SF3B1: the lord of the rings in MDS. <i>Blood</i> , 2020 , 136, 149-151	2.2	2
151	Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2020 , 136, 1851-1862	2.2	34
150	Molecular genetics of MDS/MPN overlap syndromes. 2020 , 33, 101195		2
149	Enhancing mitochondrial function in vivo rescues MDS-like anemia induced by pRb deficiency. 2020 , 88, 28-41		3

148	A presumed case of Darbepoetin-induced myocardial infarction in the patient with MDS-RARS. 2020 , 8, 658-660		1
147	Update on the classification of myeloid neoplasms: The 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms. 2020 , 3, e78		1
146	Treatment of Acquired Sideroblastic Anemias. 2020 , 34, 401-420		2
145	Novel therapies in myelodysplastic syndromes. 2020 , 27, 58-65		2
144	Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. 2020 , 15, 268-275		3
143	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. 2020 , 61, 1455-1464		2
142	SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia. 2020 , 20, 329-339.e3		2
141	MDS/MPN-RS-T justified inclusion as a unique disease entity?. 2020 , 33, 101147		0
140	Hematopathology. 2020 , 1729-2141		
139	Pathogenic diversity of RNA variants and RNA variation-associated factors in cancer development. 2020 , 52, 582-593		4
138	Roles and mechanisms of alternative splicing in cancer - implications for care. 2020 , 17, 457-474		146
137	Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. <i>Blood</i> , 2020 , 135, 1161-1170	2.2	13
136	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. 2020 , 4, 482-495		36
135	Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. 2021 , 60, 15-23		1
134	Novel frameshift variant (c.409dupG) in is a common cause of congenital sideroblastic anaemia in the Indian subcontinent. 2021 , 74, 157-162		1
133	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. 2021 , 34, 20-31		5
132	Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. 2021 , 43, 426-432		2
131	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. 2021 , 34, 904-921		1

130	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2-mutated neoplasms. 2021 , 35, 2371-2381	2
129	Quercetin induces autophagy in myelodysplastic bone marrow including hematopoietic stem/progenitor compartment. 2021 , 36, 149-167	4
128	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. 2021 , 62, 735-738	2
127	Myeloproliferative Neoplasms, Myelodysplastic/Myeloproliferative Neoplasms, and Myelodysplastic Syndromes. 2021 , 305-323	
126	Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome. 2021 , 28, 101-109	0
125	Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. 2021 , 10, 1759-1771	1
124	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. 2021 , 35, 3324-3328	0
123	Alternative splicing and cancer: a systematic review. 2021 , 6, 78	34
122	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. 2021 , 41, 328-350	0
121	Nonsense Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells with SF3B1 and U2AF1 Mutations.	
120	Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease. 2021 , 13,	1
119	References. 2021 , 301-427	
118	Myelodysplastic syndromes and overlap syndromes. 2021 , 56, S51-S64	3
117	Induced pluripotent stem cell models of myeloid malignancies and clonal evolution. 2021 , 52, 102195	0
116	The Hsp70 chaperone system: distinct roles in erythrocyte formation and maintenance. 2021 , 106, 1519-1534	3
115	SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. 2021 , 15, 3076-3090	2
114	Comparative Analysis of the Genetic Variants in Haematopoietic Stem/Progenitor and Mesenchymal Stem Cell Compartments in de novo Myelodysplastic Syndromes. 2021 , 88, 102535	2
113	Iron-sulfur cluster deficiency can be sensed by IRP2 and regulates iron homeostasis and sensitivity to ferroptosis independent of IRP1 and FBXL5. 2021 , 7,	16

112	Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration. 2021 , 10,	0
111	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. 2021 , 156, 679-690	2
110	Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia. 2021 , 10, IJH34	0
109	Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes.	
108	Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. 2021 , 34, 101280	4
107	British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. <i>British Journal of Haematology</i> , 2021 , 194, 282-293	4.5 4
106	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. 2021 , 127, 3552-3565	1
105	Clinical and pathologic challenges of clonal cytopenia of undetermined significance. 2021 , 43 Suppl 1, 82-85	1
104	Emerging roles of spliceosome in cancer and immunity. 2021 , 1	4
103	The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm. 2021 , 43, 1501-1509	1
102	Transcription Factors, R-Loops and Deubiquitinating Enzymes: Emerging Targets in Myelodysplastic Syndromes and Acute Myeloid Leukemia. 2021 , 13,	0
101	Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. 2021 , 67, 1062-1070	
100	Current and emerging strategies for management of myelodysplastic syndromes. 2021 , 48, 100791	8
99	Decreased PGC1 β expression results in disrupted human erythroid differentiation, impaired hemoglobinization and cell cycle exit. 2021 , 11, 17129	0
98	Using the Zebrafish as a Genetic Model to Study Erythropoiesis. 2021 , 22,	0
97	Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. 2021 ,	0
96	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. 2021 , 100, 1995-2004	1
95	SF3B1 mutant myelodysplastic syndrome: Recent advances. 2021 , 79, 100776	1

94	Myelodysplastic Syndrome. 2018 , 83-98	1
93	Current concepts and future directions for hemato-oncologic diagnostics. 2020 , 151, 102977	6
92	Myelodysplastic Syndromes. 2020 , 383, 1358-1374	94
91	Molecular/Cytogenetic Education for Hematopathology Fellows. 2020 , 154, 149-177	2
90	Genome-wide CRISPR screens reveal APR-246 (Eprenetapopt) triggers ferroptosis and inhibits iron-sulfur cluster biogenesis.	1
89	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. 2018 , 9, 9714-9727	42
88	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. 2019 , 10, 930-941	18
87	Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations. 2016 , 7, 9951-63	19
86	Myelodysplastic syndromes: moving towards personalized management. 2020 , 105, 1765-1779	21
85	Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations. 2021 , 106, 2906-2917	2
84	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. 2020 , 105, 2516-2523	3
83	mutation in hairy cell leukemia: A single-center experience. 2018 , 61, 532-536	2
82	Impact of next generation sequencing results on clinical management in patients with hematological disorders. 2021 , 62, 1702-1710	1
81	http://ajbm.net/952016-2/ . 2016 , 4, 360-363	
80	The Myelodysplastic Syndromes. 2018 , 483-508	
79	Myelodysplastic Syndromes With Ring Sideroblasts. 2018 , 580-583	
78	Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis. 2018 , 558-561	
77	Overview and Classification of Myelodysplastic Syndromes. 2018 , 566-575	

- 76 Hematolymphoid System. **2018**, 89-136
- 75 Pediatric myelodysplastic syndrome. **2018**, 5, 23-35 2
- 74 Immer diese Vorurteile!. **2019**, 62-66
- 73 Myelodysplastic Syndrome. **2019**, 1-21
- 72 Myelodysplastic Syndrome: An Overview. **2019**, 149-161
- 71 CRISPR editing of *sftb-1/SF3B1* in *C. elegans* allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing. ○
- 70 Presentation of a diagnostically challenging case of chronic eosinophilic leukemia with marrow dysplasia and ringed sideroblasts. **2020**, 8, 2050313X20957446
- 69 Myelodysplastic Syndrome. **2020**, 479-499
- 68 Treatment Algorithms for Lower-Risk Myelodysplastic Syndrome. **2020**, 131-145
- 67 MDS Mimics Including CHIP, ICUS, and CCUS. **2020**, 91-105
- 66 Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. **2021**, 28, 50-56 1
- 65 Morphological, Flow Cytometry, and Cytogenetic Diagnosis of MDS. **2020**, 19-42 ○
- 64 Treatment Algorithms for Higher-Risk Disease. **2020**, 147-163
- 63 Molecular Landscape of MDS. **2020**, 73-90
- 62 Myelodysplastic Syndromes (MDS). **2020**, 343-381
- 61 Clinical Presentation, Diagnosis, and Classification of Acute Myeloid Leukemia. **2021**, 11-55
- 60 Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes.
- 59 Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7. **2020**, 4, e469 ○

58	The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome. 2018 , 19, 1825-1831		1
57	Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. 2018 , 16, 56-66		8
56	[Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts]. 2020 , 41, 379-386		1
55	[Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases]. 2017 , 38, 192-197		2
54	[Research progress on clonal acquired sideroblastic anemia]. 2017 , 38, 83-86		
53	[Comparison of genetic mutations in myelodysplastic syndrome and acute myeloid leukemia]. 2021 , 42, 171-176		
52	Aberrant RNA splicing and therapeutic opportunities in cancers. 2021 ,		3
51	Coordinated mis-splicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. <i>Blood</i> , 2021 ,	2.2	2
50	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.. 2022 ,		2
49	18. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. 2020 , 109, 1983-1991		
48	Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.. 2022 , 12, 11		1
47	Recurrent Spliceosome Mutations in Cancer: Mechanisms and Consequences of Aberrant Splice Site Selection.. 2022 , 14,		0
46	How low risk are low risk myelodysplastic syndromes?. 2022 ,		1
45	SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia.. 2022 , 8, eabj8357		1
44	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. 2022 ,		1
43	Detection of p.Lys700Glu Mutation by PNA-PCR Clamping in Myelodysplastic Syndromes and Myeloproliferative Neoplasms.. 2022 , 11,		0
42	Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome.. 2022 , 24, 299-306		1
41	Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?. 2021 , 2021, 435-438		1

40	Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.. 2021 , 1-11		
39	Ineffective erythropoiesis and its treatment.. <i>Blood</i> , 2021 ,	2.2	○
38	A predictive model for bone marrow disease in cytopenia based on noninvasive procedures.. 2022 ,		○
37	Data_Sheet_1.pdf. 2020 ,		
36	Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes.. 2022 , 6, e0713		○
35	Glycolysis Dependency as a Hallmark of -Mutated Cells.. 2022 , 14,		
34	Hematological Diseases. 2022 , 73-120		
33	Somatic mutations in SF3B1 aberrant-negative MDS-RS most commonly involved in TP53 genes.. 2022 ,		
32	Computational analysis of peripheral blood smears detects disease-associated cytomorphologies.		○
31	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2022 ,	5.1	
30	Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. <i>Blood</i> ,	2.2	2
29	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.		21
28	Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. <i>British Journal of Haematology</i> ,	4.5	○
27	A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation. <i>Frontiers in Oncology</i> , 12,	5.3	
26	Myelodysplastic syndrome: epidemiology, diagnostics and epigenetic disorders. <i>Medical Herald of the South of Russia</i> , 2022 , 13, 179-190	0.2	
25	Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process. <i>Diagnostics</i> , 2022 , 12, 1658	3.8	○
24	When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms. <i>Diagnostics</i> , 2022 , 12, 1752	3.8	
23	CHIPing away the progression potential of CHIP: A new reality in the making. 2022 , 101001		○

22	Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts.	0
21	Causes and Pathophysiology of Acquired Sideroblastic Anemia. 2022 , 13, 1562	0
20	SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome. 2022 ,	1
19	Diagnosis and Treatment of Myelodysplastic Syndromes. 2022 , 328, 872	2
18	Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. 2022 , 8,	1
17	Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment. 2022 , 100920	0
16	Allogeneic stem cell transplantation for patients with myelodysplastic syndromes.	0
15	Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.	0
14	SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.	0
13	The International Consensus Classification of myelodysplastic syndromes and related entities.	0
12	Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes. 2022 , 14, 4941	0
11	Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment. 2022 , 14, 5531	0
10	Myelodysplastic syndromes. 2022 , 8,	0
9	Somatic Mutations in Myelodysplastic Syndrome Patients in the Context of Allogeneic Stem Cell Transplantation. 122-129	0
8	Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study. 2022 , 107006	0
7	Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts.	0
6	Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia. 2022 , 101039	0
5	State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. 2023 ,	0

- 4 Impact of the International Consensus Classification of myelodysplastic syndromes. ○
- 3 MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELOYDYSPLASTIC SYNDROMES WITH ISOLATED TRISOMY 8. ○
- 2 Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes. **2023**, 13, ○
- 1 Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). **2023**, 101072 ○